RxDoctor Payments Data

Paulina Maldonado

Adult Health · Long Island City, NYNPI 1760810840

Payments from drug & device makers

$13,793in general payments, 2019–2025

Across 491 payments — averaging $28.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$3K
  • Mannkind Corporation$2K
  • Abbott$1K
  • Lilly USA, LLC$879
  • Xeris Pharmaceuticals, Inc.$846
  • Boehringer Ingelheim$684
  • plus $6K from 41 others

What the payments were for

  • Food & beverage$13,793100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,793 in reported general payments places this provider in the 95th percentile of 3,828 adult health providers in New York.

See all adult health providers in New York

Medicare billing

Part B allowed, 2024
$53,331
Medicare patients
178
Services billed
801

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide352$416,420
OzempicSemaglutide331$384,792
JardianceEmpagliflozin160$189,026
TrulicityDulaglutide129$154,856
FarxigaDapagliflozin Propanediol141$145,340
RybelsusSemaglutide46$90,202
Tresiba Flextouch U-100Insulin Degludec124$71,214
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/722$35,161
Fiasp FlextouchInsulin Aspart (Niacinamide)42$31,846
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog21$21,127
JanuviaSitagliptin Phosphate12$15,960
TradjentaLinagliptin13$14,153
Novolog FlexpenInsulin Aspart82$12,411
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog31$12,383
Nano 2nd Gen Pen NeedlePen Needle, Diabetic93$12,364

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$879$571,275481 claims
Novo NordiskOzempic, Rybelsus$2,632$474,993377 claims
Boehringer IngelheimJardiance, Tradjenta$684$203,178173 claims
AstraZenecaFarxiga$55$145,340141 claims
Antares Pharma, Inc.Xyosted$327$8,43812 claims
AbbVieSynthroid$617$2,37223 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$247$1,935155 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,828 adult health providers in New York.

Other adult health in Long Island City

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →